VERONA, Italy, June 1, 2012 /CNW/ - CROMSOURCE, an international full service contract research organisation (CRO) today announced the acquisition of Pleiad, an established international CRO with offices in the US (Cambridge, Mass.) and UK (Stirling, Scotland).
Pleiad was launched in 1999, supporting clients in multiple therapy areas and with dedicated Medical Device and Ophthalmology Divisions. Additionally, Pleiad also encompasses particularly strong capabilities within statistics and data management.
'We are delighted to welcome Pleiad and its expert team', stated Dr Oriana Zerbini, Chief Executive Officer of CROMSOURCE. 'For some time we have wanted to expand and consolidate our presence in the US and we have now found the perfect way to do so. The opportunity to further add to our UK team and expand our team of experts in data management and statistics is also of great importance to us. With this collaboration CROMSOURCE reinforces its capability to support our clients with even the largest of development programmes in both Europe and the USA.'
Dr Helen Colquhoun, CEO of Pleiad, noted 'with CROMSOURCE we share a philosophy of quality, flexibility and intense customer focus. We are therefore very excited to be joining the CROMSOURCE family and working together to provide exceptional service to our current and future clients.'
About CROMSOURCE: CROMSOURCE is an ISO certified, full-service Contract Research Organization providing clinical trial services and staffing solutions since 1994. CROMSOURCE delivers clinical trials across Europe, Russia, Ukraine and the USA and operates a high quality early phase unit. CROMSOURCE provides One Trial One Price - a fixed price guarantee which assures clients that each project will be delivered according to the contract price.
For further information:
Via Scuderlando, 10
37135 Verona, Italy